Results 261 to 270 of about 157,614 (311)

Hepatitis C and steatosis

Clinics in Liver Disease, 2004
Steatosis is a common finding in patients with chronic hepatitis C (CHC) due to a combination of the direct steatogenic effect of hepatitis C virus (HCV) and the prevalence of metabolic risk factors in the HCV population. Steatosis is now established as a risk factor for disease progression in CHC and significantly impacts therapeutic response ...
Anouk, Dev, Keyur, Patel, John G, McHutchison   +2 more
openaire   +2 more sources

Patomechanisms of hepatic steatosis

Orvosi Hetilap, 2010
Az elhízás és hozzá társuló kórállapotok, így az inzulinrezisztenciát kísérő nem alkoholos zsírmájbetegség a világ egészségügyi rendszereire jelentős terhet rónak. A betegség kialakulásának első lépése a májban történő trigliceridlerakódást kísérő elzsírosodás, amely később gyulladáshoz, illetve májzsugorhoz és májrákhoz is vezethet.
Péter, Fülöp, György, Paragh
openaire   +2 more sources

Imaging of Hepatic Steatosis

Seminars in Liver Disease, 2001
Hepatic steatosis is a common finding encountered during cross-sectional imaging examinations. This article reviews the imaging findings of hepatic steatosis as revealed by sonography, computed tomography, magnetic resonance imaging, and magnetic resonance spectroscopy.
E S, Siegelman, M A, Rosen
openaire   +2 more sources

Hypertension and hepatic steatosis

Current Hypertension Reports, 2008
Hepatic steatosis (fatty liver) is increasingly recognized as a major component of the metabolic (insulin resistance) syndrome. It can progress to cirrhosis and hepatocellular carcinoma, leading to liver-related mortality. Increasing evidence shows a significant association between hepatic steatosis and hypertension; both are linked to the metabolic ...
Matthew J, Brookes, Tariq H, Iqbal, Brian T, Cooper   +2 more
openaire   +2 more sources

Drug-Induced Hepatic Steatosis

Seminars in Liver Disease, 2014
Several drugs have been associated with the potential for drug-induced hepatic steatosis (DIHS) and/or phospholipidosis (DIPL), a lysosomal storage disorder. Drug-induced hepatic steatosis is generally a chronic but reversible affliction and may involve drug accumulation in the liver.
David E, Amacher, Naga, Chalasani
openaire   +2 more sources

Hepatitis C and Steatosis

Archives of Medical Research, 2007
Hepatitis C infection and non-alcohol-related hepatic steatosis are the most common liver diseases worldwide, and both conditions often co-exist in the same patient. Hepatitis C virus (HCV) genotype 3 directly induces development of steatosis, whereas in patients with non-genotype 3 chronic hepatitis C infection, insulin resistance plays a key role in ...
Einar, Björnsson, Paul, Angulo
openaire   +2 more sources

Sphingolipids and Hepatic Steatosis

2011
The development of a fatty liver predisposes individuals to an array of health problems including diabetes, cardiovascular disease and certain forms of cancer. Inhibition or genetic ablation of genes controlling sphingolipid synthesis in rodents resolves hepatic steatosis and in many cases wards off the health complications associated with excessive ...
Benjamin T, Bikman, Scott A, Summers
openaire   +2 more sources

Hepatic Steatosis

2021
null Malak Itani, null Adeel Haq, MBBS
openaire   +1 more source

Hepatic steatosis in Hispanics

Academic Emergency Medicine, 2021
Murtaza Akhter, Albert Roh
openaire   +2 more sources

Hepatic steatosis

2022
openaire   +1 more source